• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

    2/14/23 4:11:38 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMRX alert in real time by email
    SC 13G/A 1 pt7213gaa.htm SCHEDULE 13G/A, AMENDMENT #2
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.

    Securities and Exchange Commission, Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

    (Name of Issuer)

    Chimerix, Inc.

    (Title of Class of Securities)

    Common Stock, par value $0.001 per share

    (CUSIP Number)

    16934W106

    (Date of Event Which Requires Filing of this Statement)

    December 31, 2022

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:

    [  ] Rule 13d-1(b)

    [ x ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).


    CUSIP No. 16934W106
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0
     
    (9) Aggregate amount beneficially owned by each reporting person
    0
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0%
     
    (12) Type of reporting person (see instructions) PN
     



    CUSIP No. 16934W106
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0
     
    (9) Aggregate amount beneficially owned by each reporting person
    0
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0%
     
    (12) Type of reporting person (see instructions) CO
     



    CUSIP No. 16934W106
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              63,721
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       63,721
     
    (9) Aggregate amount beneficially owned by each reporting person
    63,721
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1%
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 16934W106
    (1) Names of reporting persons    Point72 Hong Kong Limited
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Hong Kong
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0
     
    (9) Aggregate amount beneficially owned by each reporting person
    0
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0%
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 16934W106
    (1) Names of reporting persons    Point72 Middle East FZE
    (2) Check the appropriate box if a member of a group
    (see instructions)
    (3) SEC use only
    (4) Citizenship or place of organization United Arab Emirates
    Number of shares beneficially owned by each reporting person with:
    (5) Sole voting power                  0
    (6) Shared voting power              12,205
    (7) Sole dispositive power           0
    (8) Shared dispositive power       12,205
    (9) Aggregate amount beneficially owned by each reporting person
    12,205
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
    (11) Percent of class represented by amount in Row (9) <0.1%
    (12) Type of reporting person (see instructions) OO



    CUSIP No. 16934W106
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              75,926
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       75,926
     
    (9) Aggregate amount beneficially owned by each reporting person
    75,926
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1%
     
    (12) Type of reporting person (see instructions) IN
     





    Item 1(b) Address of issuer's principal executive offices:

    2505 Meridian Parkway, Suite 100, Durham, North Carolina 27713

    2(a) Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.001 per share
    (“Shares”), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors,
    Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by an investment fund
    managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (“Cubist
    Systematic Strategies”) with respect to Shares held by an investment fund it manages; (iv)
    Point72 Hong Kong Limited (“Point72 Hong Kong”) with respect to Shares held by an
    investment fund it manages; (v) Point72 Middle East FZE (“Point72 Middle East”) with respect
    to Shares held by an investment fund it manages and (vi) Steven A. Cohen
    (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management, Point72
    Capital Advisors Inc., Cubist Systematic Strategies, Point72 Hong Kong, and Point72 Middle
    East.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72
    Hong Kong, Point72 Middle East, and Mr. Cohen have entered into a Joint Filing Agreement, a
    copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have
    agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the
    Act.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of (i) Point72 Asset Management, Point72 Capital
    Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; (ii) Cubist
    Systematic Strategies is 55 Hudson Yards, New York, NY 10001; (iii) Point72 Hong Kong is
    Suites 1102 – 1110, 11th Floor and 12th Floor, Chater House, 8 Connaught Road Central, Hong Kong;
    and (iv) Point72 Middle East is EO3, 04, Sheikh Rashid Tower, Dubai World Trade Centre,
    Dubai, United Arab Emirates.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a
    Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.
    Point72 Hong Kong is a Hong Kong limited liability company. Point72 Middle East is a limited
    liability free zone establishment.   Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, par value $0.001 per share
    2(e) CUSIP Number:
    16934W106

    Item 3.

    Not applicable



    Item 4. Ownership

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for
    each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
    Such information is as of the close of business on December 31, 2022.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72
    Hong Kong, Point72 Middle East, and Mr. Cohen own directly no Shares. Pursuant to an
    investment management agreement, Point72 Asset Management maintains investment and voting
    power with respect to the securities held by an investment fund it manages. Point72 Capital
    Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment
    management agreement, Cubist Systematic Strategies maintains investment and voting power
    with respect to the securities held by an investment fund it manages. Pursuant to an investment
    management agreement, Point72 Hong Kong maintains investment and voting power with
    respect to the securities held by an investment fund it manages. Pursuant to an investment
    management agreement, Point72 Middle East maintains investment and voting power with
    respect to the securities held by an investment fund it manages. Mr. Cohen controls each of
    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72
    Hong Kong, and Point72 Middle East. The filing of this statement should not be construed as an
    admission that any of the foregoing persons or any reporting person is, for the purposes of
    Section 13 of the Act, the beneficial owner of the Shares reported herein.

    Item 5.  Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    See Item 2(a).

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities
    referred to above were not acquired and are not held for the purpose of or with the effect
    of changing or influencing the control of the issuer of the securities and were not
    cquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.


    Dated: February 14, 2023


    POINT72 ASSET MANAGEMENT, L.P.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 CAPITAL ADVISORS, INC.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    CUBIST SYSTEMATIC STRATEGIES, LLC

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 HONG KONG LIMITED

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 MIDDLE EAST FZE

    By: /s/ Rafael Lopez Espinosa
    Name: Rafael Lopez Espinosa
    Title: Authorized Person


    STEVEN A. COHEN

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person
    Get the next $CMRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMRX

    DatePrice TargetRatingAnalyst
    5/23/2023$7.00Outperform
    Robert W. Baird
    9/7/2022$7.00Overweight
    CapitalOne
    12/22/2021$21.00 → $24.00Buy
    HC Wainwright & Co.
    11/22/2021$19.00 → $21.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CMRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

      New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2024. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chi

      3/21/25 6:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4). The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, wi

      3/7/25 4:01:00 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

      -Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz's pipeline- -Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") and Chimerix (NASDAQ:CMRX) ("Chimerix"), today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million. The transaction has been approved by both compani

      3/5/25 7:00:00 AM ET
      $CMRX
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Chimerix with a new price target

      Robert W. Baird initiated coverage of Chimerix with a rating of Outperform and set a new price target of $7.00

      5/23/23 7:29:20 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Chimerix with a new price target

      CapitalOne initiated coverage of Chimerix with a rating of Overweight and set a new price target of $7.00

      9/7/22 8:57:44 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Chimerix with a new price target

      HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $24.00 from $21.00 previously

      12/22/21 6:12:39 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Middleton Fred A bought $16,522 worth of shares (17,295 units at $0.96) (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      11/20/23 3:28:44 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Middleton Fred A bought $2,489 worth of shares (2,705 units at $0.92) (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      11/13/23 4:39:41 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Middleton Fred A bought $19,636 worth of shares (20,000 units at $0.98) (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      9/26/23 3:58:48 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Chimerix Appoints Marc D. Kozin to Board of Directors

      DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo

      3/21/24 7:00:00 AM ET
      $CMRX
      $UFPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Chimerix Appoints Lisa Decker to Board of Directors

      DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors. Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service. "We are delighted to welcome Lisa to the Chimerix Board of Directors. She brings a wealth of scientific expertise, oncology drug development and business development experience that will be important assets to

      12/29/23 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

      DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. "We are excited to welcome Tom to the Chimerix team as his leadership and extensive market knowledge will be a great asset as we advance ONC201 toward commercialization," said Mike Andriole, Chief Executive Officer of Chimerix. "Tom's in-depth oncology experience in commercial launch readiness, brand marketing, market access, and reimbursement will accelerate our readiness efforts

      11/16/23 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Chimerix Inc.

      15-12G - CHIMERIX INC (0001117480) (Filer)

      5/1/25 8:51:45 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Chimerix Inc.

      EFFECT - CHIMERIX INC (0001117480) (Filer)

      4/23/25 12:15:12 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chimerix Inc.

      S-8 POS - CHIMERIX INC (0001117480) (Filer)

      4/21/25 4:54:30 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Financials

    Live finance-specific insights

    See more
    • Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

      New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2024. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chi

      3/21/25 6:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

      Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recu

      12/9/24 4:01:00 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

      – Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment with TGA to Submit Dordaviprone for Provisional Approval in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2024 and provided an operational update. "We have sustaine

      11/7/24 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Vakiener Victoria

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:17:40 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Sherman Michael A. returned $3,620,138 worth of shares to the company (423,408 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:16:42 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO and CCO Riga Thomas J returned $520,079 worth of shares to the company (60,828 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:15:59 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

      SC 13G/A - CHIMERIX INC (0001117480) (Subject)

      2/14/24 5:01:40 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

      SC 13G/A - CHIMERIX INC (0001117480) (Subject)

      2/12/24 6:06:37 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Chimerix Inc.

      SC 13G - CHIMERIX INC (0001117480) (Subject)

      9/29/23 4:54:06 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care